NCT05741242
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Enrolling by Invitation
PHASE1Ages 12+InterventionalTreatmentJaime Leandro Foundation for Therapeutic Cancer VaccinesInvestigator-initiated
~136 participants
Updated 2026-01-15 on ClinicalTrials.gov
What's tested:Personalized Synthetic Long Peptide Vaccine
At a glance
Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).
Measured over Until progression or death, assessed up to 12 months post first vaccine administration.
Conditions
Where it's being run
5 sites across 4 statesCalifornia2
Florida1
Missouri1
New York1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).Until progression or death, assessed up to 12 months post first vaccine administration.
Progression-Free Survival at 12 months (PFS12) defined as time from first vaccine administration until disease progression by investigator assessment or death due to any cause.